Lifeboat Foundation

Sleep has critical roles in health and regeneration, and one of those is clearing the brain of metabolic waste, according to researchers from the US and Denmark.

Now, as reported in the journal Nature Communications, they’ve discovered in mice that the time of day matters, suggesting the process is controlled by circadian rhythms.

“Our group has shown that just being awake or asleep drastically changes how well the brain can clear waste,” says lead author Lauren Hablitz from the University of Rochester Medical Centre.

Circa 2019 o.o

A grizzly’s body can slow down for months without damage. Researchers wonder if the ability can be harnessed to aid human health.

Ira Pastor ideaXme life sciences ambassador with Tom Lawry Microsoft on the ideaXme page — Facebook LIVE tomorrow! #health #microsoft #ideaxme #movethehumanstoryforward #medtech #medtechlife🔬💉 #microsofthealthcare #microsofthealthapp #healthcare

Recorded Live

EURO GENÇ TV

A pioneer in Emotion AI, Rana el Kaliouby, Ph.D., is on a mission to humanize technology before it dehumanizes us.

At LiveWorx 2020, Rana joined us to share insights from years of research and collaboration with MIT’s Advanced Vehicle Technology group.

Part demo and part presentation, Rana breaks down the facial patterns that cameras can pick up from a tired or rested driver, and observations from the first ever large-scale study looking at driver behavior over time.

Continue reading “Artificial Emotional Intelligence (Emotion AI) – What It Is and Why It Matters” »

Providence, R.I. — The federal government has told states to prepare for a coronavirus vaccine to be ready to distribute by Nov. 1.

The timeline raised concern among public health experts about an “October surprise” — a vaccine approval driven by political considerations ahead of a presidential election, rather than science.

In a letter to governors dated Aug. 27, Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, said states “in the near future” will receive permit applications from McKesson Corp., which has contracted with CDC to distribute vaccines to places including state and local health departments and hospitals.

Medical experts say coronavirus COVID-19 and Ebola outbreaks show that robotic medicine can help fight infectious disease, but the goal needs to be applications in everyday health care.

When we came out of the financial crisis of 2008, cloud computing kicked into high gear and started to become a pervasive, transformational technology. The current COVID-19 crisis could provide a similar inflection point for AI applications. While the implications of AI continue to be debated on the world stage, the rapid onset of a global health crisis and concomitant recession will accelerate its impact.

Times of crisis bring rapid change. Efforts to harness AI technologies to discover new drugs – either vaccine or treatment – have kicked into hyperdrive. Startups are racing to find solutions and established companies are forming partnerships with academia to find a cure. Other companies are researching existing drugs for their potential applicability. AI is proving a useful tool for dramatically reducing the time needed to identify potential drug candidates, possibly saving years of research. AI uses already put into action are screening for COVID-19 symptoms, decision support for CT scans, and automating hospital operations. A variety of healthcare functions have started to be performed by robots, from diagnosis to temperature monitoring.

Whatever the new normal becomes in the aftermath of the current crisis, it’s apparent that AI will be an even larger part of the technology landscape going forward — and not only for healthcare.

Cardiovascular-related disorders are a significant worldwide health problem. Cardiovascular disease (CVD) is the leading cause of death in developed countries, making up a third of the mortality rate in the US¹. Congenital heart defects (CHD) affect ∼1% of all live births², making it the most common birth defect in humans. Current technologies provide some insight into how these disorders originate but are limited in their ability to provide a complete overview of disease pathogenesis and progression due to their lack of physiological complexity. There is a pressing need to develop more faithful organ-like platforms recapitulating complex in vivo phenotypes to study human development and disease in vitro. Here, we report the most faithful in vitro organoid model of human cardiovascular development to date using human pluripotent stem cells (hPSCs). Our protocol is highly efficient, scalable, shows high reproducibility and is compatible with high-throughput approaches. Furthermore, our hPSC-based heart organoids (hHOs) showed very high similarity to human fetal hearts, both morphologically and in cell-type complexity. hHOs were differentiated using a two-step manipulation of Wnt signaling using chemical inhibitors and growth factors in completely defined media and culture conditions. Organoids were successfully derived from multiple independent hPSCs lines with very similar efficiency. hHOs started beating at ∼6 days, were mostly spherical and grew up to ∼1 mm in diameter by day 15 of differentiation. hHOs developed sophisticated, interconnected internal chambers and confocal analysis for cardiac markers revealed the presence of all major cardiac lineages, including cardiomyocytes (TNNT2⁺), epicardial cells (WT1⁺, TJP⁺), cardiac fibroblasts (THY1⁺, VIM⁺), endothelial cells (PECAM1⁺), and endocardial cells (NFATC1⁺). Morphologically, hHOs developed well-defined epicardial and adjacent myocardial regions and presented a distinct vascular plexus as well as endocardial-lined microchambers. RNA-seq time-course analysis of hHOs, monolayer differentiated iPSCs and fetal human hearts revealed that hHOs recapitulate human fetal heart tissue development better than previously described differentiation protocols^3,4. hHOs allow higher-order interaction of distinct heart tissues for the first time and display biologically relevant physical and topographical 3D cues that closely resemble the human fetal heart. Our model constitutes a powerful novel tool for discovery and translational studies in human cardiac development and disease.

The authors have declared no competing interest.